Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937944 | 1.00 | CA1 (0.58) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL745037 | 0.97 | — | — | |
| SCHEMBL1935164 | 0.90 | — | — | |
| SCHEMBL22003894 | 0.82 | — | — | |
| SCHEMBL2261416 | 0.82 | POLB (0.42) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL5280013 | 0.76 | POLB (0.93) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL29905605 | 0.76 | POLB (0.93) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL9540497 | 0.73 | CA1 (0.58) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL21356989 | 0.73 | CA1 (1.00) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL392889 | 0.73 | CA1 (1.00) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120059400-A | Copper-clad plate with high adhesive force and manufacturing method thereof | 江门建滔电子发展有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119081574-A | Flame-retardant PET (polyethylene terephthalate) adhesive tape and preparation method thereof | 常州市白鹭电器有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-3077373-B1 | PREPARATION OF COBICISTAT INTERMEDIATES | MYLAN LABORATORIES LTD (IN) | 2018-09-12 | — | — | EP | claimed |
| US-20160297780-A1 | Preparation of Cobicistat Intermediates | Mylan Laboratories Ltd. (IN) | 2016-10-13 | — | — | US | claimed |
| EP-3077373-A1 | PREPARATION OF COBICISTAT INTERMEDIATES | Mylan Laboratories Ltd. (IN) | 2016-10-12 | — | — | EP | claimed |
| WO-2015083066-A1 | PREPARATION OF COBICISTAT INTERMEDIATES | Mylan Laboratories Ltd. (IN) | 2015-06-11 | — | — | WO | claimed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-120192251-A | Sulfonamide compound for resisting prostate cancer and application thereof | 浙江大学 | 2025-06-24 | — | — | CN | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| CN-120059400-A | Copper-clad plate with high adhesive force and manufacturing method thereof | 江门建滔电子发展有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-4148659-A | NONSILVER PHOTOGRAPHY | AGFA-GEVAERT N.V. (BE) | 1979-04-10 | — | — | US | disclosed |
| US-4075351-A | INHIBITION OF MALE FERTILITY WITH ALIPHATIC SULFAMATES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4066778-A | ANTIBACTERIAL, ANTIPROTAZOA, ANTHELMINTIC | CIBA-GEIGY CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
| US-3997585-A | Aliphatic sulfamates | ORTHO PHARMACEUTICAL CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3976778-A | ANTHELMINTIC, BACTERICIDE, ANTIPROTOZOA | CIBA-GEIGY CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3951959-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951958-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | CA1 4783/4885CA2 4314/4885POLB 1018/4885 |
| US-20160297780-A1 | Preparation of Cobicistat Intermediates | PARP8, PARP9, PRSS8 | CA1 2959/4885CA2 2741/4885POLB 844/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | CA1 4823/4885CA2 3864/4885POLB 4585/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | CA1 4838/4885CA2 4297/4885POLB 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.